Figure 2

Association of the BRCA-like^CGHstatus with overall survival after HD-CTC and conventional chemotherapy. Kaplan-Meier survival curves for OS were generated separately for all HER2-negative breast cancer patients with BRCA-like^CGH(A) and with non-BRCA-like^CGH(B) tumors; for the subgroup of TNBC patients with BRCA-like^CGH(C) and with non-BRCA-like^CGH(D) tumors; and for the subgroup of hormone receptor-positive, HER2-negative breast cancer patients with BRCA-like^CGH(E) and with non-BRCA-like^CGH tumors (F); who had been randomly assigned between HD-PB chemotherapy and conventional chemotherapy. FE₉₀C, 5-fluorouracil, epirubicin, cyclophosphamide; HD-CTC, high-dose cyclophosphamide-thiotepa-carboplatin; HD-PB, high-dose platinum-based; HR-pos, hormone receptor-positive; OS, overall survival; TNBC, triple-negative breast cancer.